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Background: Canine mammary sarcomas (CMSs) are rarely diagnosed in female dogs, which explains the scarcity
of immunohistochemical findings concerning those tumors. This paper presents the results of a retrospective study
into CMSs and discusses the clinical features of the analyzed tumors, the expression of intermediate filaments CK,
Vim, Des and α-SMA, and the expression of p63, Ki67, ERα, PR and p53 protein.
Results: Four percent of all canine mammary tumors (CMTs) were classified as CMSs, and they represented 5.1% of
malignant CMTs. The mean age at diagnosis was 11.1 ± 2.8 years. Large breed dogs were more frequently affected
(38.7%). The majority of observed CMSs were fibrosarcomas (2.1%). All CMSs expressed vimentin, and higher levels
of vimentin expression were noted in fibrosarcomas and osteosarcomas. Ki67 expression was significantly correlated
with the grade of CMS.
Conclusions: Our results revealed that CMSs form a heterogeneous group, therefore, immunohistochemical
examinations could support differential and final diagnosis. Although this study analyzed a limited number of
samples, the reported results can expand our knowledge about CMSs. Further work is required in this field.
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Canine mammary tumors (CMTs) are the most com-
mon neoplasms that account for nearly one-half of all
tumors diagnosed in female dogs. Approximately 41%
to 53% of CMTs are malignant [1,2]. Most CMTs are
epithelial in origin, and they have been extensively
researched [3,4]. However, little is known about canine
mammary sarcomas (CMSs), which are malignant tumors
originating in mesenchymal tissue of the mammary
gland, including osteosarcoma, chondrosarcoma, fibro-
sarcoma and hemangiosarcoma [5,6]. They are consid-
ered to have a very poor prognosis and, therefore, pose
a great challenge in veterinary practice [1,6,7]. Mam-
mary sarcomas are more often diagnosed in dogs than
humans where breast sarcomas constitute less than 1%
of malignant breast tumors [8]. The discussed tumors
are very rare, they remain poorly investigated, and the
majority of published studies into CMSs involve case* Correspondence: izabella_dolka@sggw.pl
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reproduction in any medium, provided the orreports or experiments performed on a small number of
samples [7,9-12].
To the best of our knowledge, this study is the first
ever immunohistochemical analysis of CMSs. The aim of
this research was two-fold: to perform a retrospective
analysis (1996–2012) into the percentage of CMSs in all
CMTs, to determine the age and breed of affected fe-
males, and to evaluate the expression of intermediate fil-
aments: vimentin (Vim), cytokeratin (CK), alpha smooth
muscle actin (α-SMA) and desmin (Des) as well as the
expression of p63 protein, Ki67 antigen, estrogen recep-
tor alpha (ERα), progesterone receptor (PR), and p53
protein by immunohistochemical staining.
Methods
Tumor samples and histopathological examination
In this study, all cases of CMTs described in the archives
(1996–2012) of the Division of Animal Pathomorphology
at the Department of Pathology and Veterinary Diagnostics
have been analyzed. The histological type of the tumor was
assessed based on the World Health Organization (WHO)
Histological Classification of the Mammary Tumors of the
Dog and Cat, the histological grade was based on thetd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ation and the mitotic index [13,14]. For the needs of this
study, CMTs were classified as benign or malignant, and
were further subdivided into carcinomas and sarcomas.
The age at diagnosis, the affected animal breed and the
morphological features of the tumor, including size, loca-
tion and histological type, were recorded. Eighteen paraffin-
embedded specimens of canine mammary sarcomas were
analyzed. The final diagnosis was based on IHC results and
tumor grade. The histological type of CMS was determined
based on the proposed criteria [6] and the World Health
Organization classification [14]. The mitotic index (MI)
was determined as the mean number of cells in mitosis
evaluated in 10 high-power fields (HPF) under 40x object-
ive lens (field area 0.239 mm2) [15]. A specific grading sys-
tem for CMSs has not yet been established, therefore, the
method used in this study was based on the degree of cell
differentiation (pleomorphism), the mitotic index and the
presence of necrosis. CMSs were classified into two groups:
low-grade malignancy (well-differentiated and moderately
differentiated, I and II) and high-grade malignancy (poorly
differentiated, III) [16]. Where an agreement on a diagnosis
could not be achieved, a round-table discussion was staged
using a multi-headed microscope.
Immunohistochemical examination (IHC)
Eighteen CMS specimens were subjected to immunohis-
tochemical (IHC) analysis. Five micrometer (μm) thick
sections were mounted onto a glass slide covered with
2% Silan solution in acetone. After dewaxing in xylene
and rehydration in ethanol for antigen retrieval, the
slides were heated in a microwave oven in 0.02 M citrate
buffer, pH 6.0. After cooling, the sections were incubated
in 3% perhydrol solution for 15 minutes to block the en-
dogenous peroxidase reaction. Non-specific binding was
blocked by incubation in 5% bovine serum albumin
(Sigma Aldrich, Germany). After 30 min, the following
primary antibodies (diluted in 1% bovine serum) were
used: monoclonal mouse anti-human vimentin, Vim
(clone Vim 3B4, Dako, Denmark) diluted 1:50 [17,18],
monoclonal mouse anti-human cytokeratin, CK (clone
MNF116, Dako, Denmark) diluted 1:50 [17,18], mono-
clonal mouse anti-human alpha smooth muscle actin, α-
SMA (clone 1A4, Dako, Denmark) diluted 1:100 [19],
monoclonal mouse anti-human desmin, Des (clone D33,
Dako, Denmark) diluted 1:50 [17-19], monoclonal mouse
anti-p63 protein (clone 4A4, Santa Cruz Biotechnology,
USA) [20], mouse monoclonal anti-human Ki67 (clone
MIB-1, Dako, Denmark) diluted 1:75 [15,21,22], rabbit
polyclonal anti-human estrogen receptor alpha, ERα (H-
184, Santa Cruz Biotechnology, USA) diluted 1:100 [23],
ready-to-use mouse monoclonal anti-human progesterone
receptor, PR (clone PR10A9, Immunotech, France) [24,25]
and rabbit polyclonal anti-human p53 protein (cloneFL-393, Santa Cruz Biotechnology, USA) diluted 1:50
[25,26]. The slides were incubated in a humidified
chamber for 1 h at room temperature. A biotinylated
secondary antibody (EnVision + System-HRP, Dako,
Denmark) was used in accordance with the manufac-
turer’s instructions. The sections were washed, covered
with diaminobenzidine chromogen (DAKO) and coun-
terstained with Mayer's hematoxylin for 10 min. They
were dehydrated in a graded series of alcohols, cleared
in xylene and mounted using the DPX medium (Gurr®,
Sigma-Aldrich) and coverslips. Paraffin-embedded neo-
plastic canine tissues and healthy tissues with known
positive reactivity were used as extrinsic and/or intrinsic
positive controls. Negative controls were also performed
by omitting the primary antibody.
Scoring of immunohistochemical data
Immunohistochemical analyses involved at least 10 images
of sarcomatous areas acquired at x40 HPF (Olympus
microscope BX41). Positive immunostaining for Vim, CK,
Des and α-SMA was observed as a brown cytoplasmic
precipitate, and for p63 – as a brown nuclear precipi-
tate. The number of immunoreactive cells was classified
as: - = none, ± = slight (positive cells constituted less
than 10%); + = moderate (10–50% of cells were positive);
and ++ = intense (more than 50% of cells were positive)
[20]. The colorimetric intensity of IHC-stained antigen
spots was determined in a computer-assisted image
analyzer (Olympus Microimage Image Analysis version 4.0
for Windows, USA), and antigen spot color intensity was
expressed as mean pixel optical density on a 1–256 scale.
Positive immunostaining for Ki67, ERα, PR and p53 was
defined as nuclear pattern (brown precipitate). Antigen
density was determined by counting at least 1000 cells in
10 HPF. The number of positive cells was expressed as the
percentage of positively stained cells in the total number
of cells [21,27]. Areas with necrosis were omitted.
Statistical analysis
Data was processed in Prism 5.00 software (GraphPad Soft-
ware, California, USA) using one-way ANOVA, Tukey's
HSD (Honestly Significant Difference) post-hoc test, Spear-
man's and Pearson's correlation. P-values <0.05 (*) were
regarded as significant, whereas p-values <0.01 and <0.001
were considered to be highly significant.
Results
Retrospective data for CMSs
A total of 841 CMT cases were found in the archives
(1996–2012) of the Division of Animal Pathomorphol-
ogy. CMSs constituted only 4% (34/841) of all CMTs
and 5.1% (34/666) of malignant CMTs. The ratio of sarco-
mas to carcinomas was 1:18 (34/616). Malignant mixed
mammary tumors (carcinosarcomas) were excluded from
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was 11.1 ± 2.8 years, within a range of 5 to 17 years.
The mean tumor size, defined as the largest diameter,
was 8.8 ± 6.1 cm (range of 2–20 cm). The fourth left
mammary gland was most commonly affected. In the
group of purebred dogs, the percentage of CMSs was
higher in large breeds (38.7%, n = 12), i.e. German
Shepherds (n = 4) and Rottweilers (n = 2), and single
CMS cases were noted in the following breeds: St. Bernard,
Tosa Inu, Doberman Pinscher, Flat Coated Retriever,
Labrador Retriever and German Shorthaired Pointer.
A lower percentage of CMSs was noted in mongrels and
small breeds (both 25.8% and n = 8), but it was very rarely
encountered in medium-sized dog breeds (9.7%, n = 3).
The breed of three dogs was not identified. The histo-
logical types of CMSs and their percentage distribution
were follows: 2.1% fibrosarcoma (n = 14), 1.1% osteosar-
coma (n = 7), 0.9% liposarcoma (n = 6), 0.6% chondrosar-
coma (n = 4), 0.3% hemangiosarcoma (n = 2) and 0.2%
unclassified sarcoma (n = 1).
Immunohistochemical analysis of CMSs
A total of 52.9% (n = 18) of CMS specimens, including 8
osteosarcomas, 6 fibrosarcomas, 2 liposarcomas, 1 chon-
drosarcoma and 1 unclassified sarcoma, were subjected toFigure 1 Histological and immunohistochemical images of canine ma
standard hematoxylin and eosin (H-E) method. Immunopositivity (nuclear o
The EnVision + System-HRP detection system was used, and the signal was
indicate positive nuclear staining of cells. An asterisk (*) indicates a negativ
Olympus BX41 microscope. Original magnification: H-E (x400), Vim (x400), αimmunohistochemical examination. Individual cases were
placed in a single group termed ‘other sarcomas’.
The analyzed specimens included 16 high-grade and 2
low-grade CMSs. All osteosarcomas, liposarcomas and
other sarcomas were high-grade tumors; 66.7% (n = 4) of
fibrosarcomas were high-grade, whereas the remaining
fibrosarcomas were classified as low-grade. No significant
differences were observed between patients' age or breed,
tumor size, sarcoma type or degree of malignancy.
The staining pattern was evaluated in sarcomatous areas
of the tumor (Figures 1, 2, 3 and 4). All 18 cases were
positive for Vim. The mean optical density related to Vim
expression in liposarcomas and other sarcomas was sig-
nificantly lower than in osteosarcomas and fibrosarcomas
(p <0.05) (Figure 5A, 5B). Focal moderate (+) expression
of α-SMA was found in osteosarcomas (n = 3) and fibro-
sarcomas (n = 3) (Figures 1 and 2). Moderate cytoplasmic
expression of α-SMA and Des was observed in one fibro-
sarcoma cell (Figure 2). The expression of CK and p63
was not observed in neoplastic cells. Ki67 was expressed
by all CMSs, p53 – by 50% CMSs (n = 9), PR – by 27.8%
(n = 5), and ERα expression was reported only in one sam-
ple (Figures 1, 2, 3 and 4). Detailed data is given in Tables 1
and 2. Spearman's analysis revealed that Ki67 expression
(p = 0.034) was significantly correlated with the CMSmmary osteosarcoma. The histological sample was stained with the
r cytoplasmic) is shown as brown precipitate in neoplastic cells.
visualized with chromogen 3,3-diaminobenzidine 3-3' (DAB). Arrows
ely stained sarcomatous area. Images were obtained under the
-SMA (x400), Ki67 (x400), ERα (x200, x400), PR (x400), p53 (x400).
Figure 2 Histological and immunohistochemical images of canine mammary fibrosarcoma. The histological sample was stained with the
standard hematoxylin and eosin (H-E) method. Positive immunostaining (nuclear or cytoplasmic) was observed as brown precipitate. The
EnVision + System-HRP detection system was used, and the signal was visualized with chromogen 3,3-diaminobenzidine 3-3' (DAB). Arrows
indicate positive nuclear staining of cells. An asterisk (*) indicates a negatively stained sarcomatous area. Images were obtained under the
Olympus BX41 microscope. Original magnification: H-E (x400, arrow indicates a mitotic figure), Vim (x400), α-SMA (x400), Des (x400), Ki67 (x400),
PR (x200; arrow indicates PR-positive epithelial cells of the mammary gland duct); PR (x400), p53 (x400).
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tween proliferation markers (Ki67 expression and MI) and
the expression levels of hormone receptors ERα and PR.
Discussion
Canine mammary sarcomas (CMSs) are a rare type of
tumors, and little is known about their biology. Our
results provide new insights into clinical data regarding
CMSs. Researchers are divided over the frequency of CMS
occurrence. Previous research demonstrated that CMSs
accounted for a small percent (0.45-16.7%) of CMTs
[5,28,29], and similar results were reported in our study.
According to some authors, CMSs constitute 40% of all
mammary malignancies [29,30]. It should be noted, how-
ever, that in selected analyses, carcinosarcomas were in-
cluded in the group of sarcomas [31]. In this study, CMSs
were observed in older female dogs, which is consistent
with reports describing the mean age at CMT diagnosis
[3,32]. One study found that younger dogs (mean age of 9
years) were more likely to be affected by CMSs than ca-
nine mammary carcinomas [5], but other morphological
features were similar to those reported by Misdorp et al.
[5]. Interestingly, we noted that CMSs were more likely to
affect the left rather than the right mammary gland. How-
ever, considering the small number of samples and thescarcity of published data, our results could be purely co-
incidental. In view of previous reports indicating that the
location of the tumor had no effect on the outcome, the
above information has no clinical significance [2,32].
Selected studies indicated that purebred dogs were
more predisposed to mammary tumors than mongrels
[33]. In a survey of 101 CMTs, one case of sarcoma was
observed in small-breed dog and another in a different
dog breed [34]. In our study, the majority of CMSs
were diagnosed in large-breed dogs. To date, only one
study has demonstrated that CMSs were common in
medium- and large-breed dogs [11]. In our opinion, the
fact that CMSs are most frequently observed in large-
breed dogs could be attributed to the high popularity of
those breeds in Poland. Due to a limited number of
cases, breed predilection for only CMSs has not been
established, but it has been reported for all canine
mammary tumors [1,28,33].
In the retrospective analysis, fibrosarcoma was the most
frequent type of sarcoma in the group of malignant CMTs.
Our results corroborate the findings of other authors
[5,35]. Gómez et al. [35] described fibrosarcoma as the
second most common malignant CMT after carcinoma.
Fibrosarcoma affected 1.3-5.56% of the populations sur-
veyed in different studies [36,37].
Figure 4 Histological and immunohistochemical photographs of other canine mammary sarcomas. The histological sample was stained
with the standard hematoxylin and eosin (H-E) method. Immunopositivity (nuclear or cytoplasmic) is shown as brown precipitate in neoplastic
cells. The EnVision + System-HRP detection system was used, and the signal was visualized with chromogen 3,3-diaminobenzidine 3-3' (DAB).
Arrows indicate positive nuclear staining of cells. The images were obtained under the Olympus BX41 microscope. Original magnification: H-E
(x100), Vim (x400), Ki67 (x400), PR (x400), p53 (x1000).
Figure 3 Histological and immunohistochemical images of canine mammary liposarcoma. The histological sample was stained with the
standard hematoxylin and eosin (H-E) method. Immunopositivity (nuclear or cytoplasmic) is shown as brown precipitate in neoplastic cells.
The EnVision + System-HRP detection system was used, and the signal was visualized with chromogen 3,3-diaminobenzidine 3-3' (DAB). Arrows
indicate positive nuclear staining of cells. The images were obtained under the Olympus BX41 microscope. Original magnification: H-E (x400),
Vim (x400), Ki67 (x1000), PR (x400), p53 (x400).
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Figure 5 Vimentin (Vim) expression in canine mammary sarcomas of various histological type. (A) Representative images of CMSs
obtained under the Olympus BX41 microscope. Positive staining for Vim is observed as brown precipitate in the cytoplasm of neoplastic cells.
The EnVision + System-HRP detection system was used, and the signal was visualized with chromogen 3,3-diaminobenzidine 3-3' (DAB). (B) The
graph represents integrated optical density (IOD) of vimentin-positive cells in canine mammary sarcomas. The colorimetric intensity of IHC-stained
antigen spots was determined in a computer-assisted image analyzer (Olympus Microimage™ Image Analysis version 4.0 for Windows, USA), and
the color intensity of the antigen spot is expressed as mean pixel optical density on a 1–256 scale. The results are presented as the mean (±SEM)
from all tumors in each group. Data was processed in Prism 5.00 software (GraphPad Software, California, USA) using one-way ANOVA and Tukey's
HSD post-hoc test. P-values <0.05 (*) were regarded as significant and marked with an asterisk (*).
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monly accepted. Several studies described malignant pro-
gression from complex carcinomas to simple carcinomas
and sarcomas [1,32]. In our study, the majority (88.9%) of
the examined CMSs were high-grade tumors, but no sig-
nificant correlation was observed between the histological
type and the grade of CMSs. The above could be attrib-
uted to the small number of samples and the low statis-
tical power to detect differences.
The origin of mesenchymal tumors and mesenchymal
elements (in particular cartilage and bone) in the mammaryTable 1 Immunoreactivity for intermediate filaments and p63
Immunoreactivity for interm
Group of CMS N Vim CK
- ± + ++ - ± + ++
Osteosarcoma 8 0 0 0 8 8 0 0 0
Fibrosarcoma 6 0 0 0 6 6 0 0 0
Liposarcoma 2 0 0 0 2 2 0 0 0
Other sarcomas 2 0 0 0 2 2 0 0 0
N = number of cases, CMS = canine mammary sarcoma, Vim = vimentin, CK = cytoke
immunoreactive cells was classified as: - = none; ± = slight (positive cells constituted
(more than 50% of cells were positive).gland has been under debate for many years. Some authors
suggested that mesenchymal components originated from
myoepithelial cells [20] or pluripotent stem cells [38]. Stu-
dies of CMT histogenesis examined the expression of mi-
crofilaments [1,6,9,17]. Analyses of intermediate filament
expression support differentiation between canine mam-
mary sarcomas (in particular fibrosarcomas and spindle
cell carcinomas or malignant myoepitheliomas and he-
mangiopericytomas). All CMSs examined in our study
showed expression of Vim (at various levels) regardless of
their histological type, which could indicate that theyin the analyzed CMS groups
ediate filaments and p63
α-SMA Des p63
- ± + ++ - ± + ++ - ± + ++
4 1 3 0 8 0 0 0 8 0 0 0
3 0 3 0 4 1 1 0 6 0 0 0
1 1 0 0 2 0 0 0 2 0 0 0
2 0 0 0 2 0 0 0 2 0 0 0
ratin, α-SMA = alpha smooth muscle actin, Des = desmin. The number of
less than 10%); + =moderate (10-50% of cells were positive); and ++ = intense
Table 2 Frequency of positively stained cases of CMS
investigated for the expression of Ki67, ERα, PR and p53
according to histological type and grade
Frequency of Ki67, ERα, PR and p53 immunopositivity
Group of CMS N Ki67 N(%) ERα N(%) PR N(%) p53 N(%)
Osteosarcoma 8 8(100) 1(12.5) 1(12.5) 4(50)
Fibrosarcoma 6 6(100) 0(0) 2(33.3) 3(50)
Liposarcoma 2 2(100) 0(0) 1(50) 1(50)
Other sarcomas 2 2 (100) 0(0) 1(50) 1(50)
Grade of CMS N
High-grade 16 16(100) 1(6.3) 4(25) 9(56.3)
Low-grade 2 2(100) 0(0) 1(50) 1(50)
Total 18 18(100) 1 (5.6) 5(27.8) 9(50)
N = number of cases.
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expression levels of Vim could be related to differences in
CMS structure. Terra et al. [40] recently reported signi-
ficantly higher expression of vimentin in malignant canine
mammary tumors than in benign lesions. To the best of
our knowledge, there are no published reports regarding
CMSs. In this study, the expression of α-SMA was ob-
served in three osteosarcomas and three fibrosarcomas,
and Des expression was noted in one case of fibrosar-
coma. Those observations could point to myofibroblastic
focal differentiation that was previously described in feline
mammary and breast sarcomas [41,42]. Some authors sug-
gested the myoepithelial origin of myofibroblasts [43], but
the absence of CK and p63 immunoreactivity combined
with strong Vim expression in this study points to the mes-
enchymal nature of CMSs. Myofibroblastic differentiationFigure 6 Proliferation activity based on the mean values of the
Ki67 index and its correlation with malignancy grade. Data was
processed by ANOVA + Tukey HSD post-hoc tests (Graph Pad Prism
5.0). P-values <0.05 (*) were regarded as significant and marked with
an asterisk (*).was observed in breast malignancies (malignant fibrous his-
tiocytoma, low-grade myofibroblastic sarcoma) [42,44], but
it was not noted in mammary tumors in animals.
In this study, CK expression was not observed in any
of the examined CMSs. Our findings are consistent with
previously published reports where no direct transitions
between carcinoma and sarcoma were noted [13,14]. In
two reports [9,17], CK expression was observed in canine
mammary osteosarcomas, and it was limited to epithelial-
like cells.
In the present study, high levels of Ki67 expression
were noted in the examined CMSs. In other studies, cell
proliferation activity varied significantly across different
histologic grades [15,45]. In our study, the expression of
Ki67 was correlated with the sarcoma grade. According
to many authors, proliferative activity can predict the
biological behavior of canine mammary carcinomas:
metastases, disease-free survival (DFS) and overall sur-
vival (OS) [15,21,45,46]. Canine mammary sarcomas
were characterized by higher levels of Ki67 expression
than carcinomas [21].
To the best of our knowledge, the expression of p53 in
CMSs has been investigated by very few authors [47,48].
Similar expression levels of p53 in various types of CMSs
(mostly high grade sarcomas) were demonstrated in this
study. This is a relative new observation, and to date, p53
expression has been demonstrated mainly in osteosar-
comas [47,49]. Our findings could suggest that p53 plays a
role in malignant progression of the tumor [27,50]. Over-
expression of p53 has been described in 50% of breast sar-
comas [50]. Those results largely corroborate our findings.
Interestingly, other authors have suggested the possible
prognostic role of p53 expression in breast sarcomas [50].
Similar results were noted in this study, but the utility of
p53 as a prognostic maker should be examined on a larger
number of samples and in view of follow-up data.
Most of the examined CMSs showed no expression of
ERα or PR. In literature, high levels of ERα and PR have
been observed in well-differentiated tumors with a low
proliferation rate [21,22]. Hormonal therapy is thought
to be beneficial in those types of tumors [22,51]. As ex-
pected, although the majority of CMSs were hormone-
independent, ERα and PR expression was not correlated
with tumor type or grade. Those findings support our
observations that hormonal treatment, which is often
recommended in mammary carcinomas [24], could be
ineffective in sarcomas due to an absence of hormone
receptors [52]. The differences between the hormonal
status of carcinomas and sarcomas could be attributed
to variations in their histogenetic origin. Our study dem-
onstrated an absence of correlations between ERα and
PR expression and proliferation status. Hormone recep-
tors did not show antiproliferative activity that is ob-
served in mammary cancers [46,51].
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According to our best knowledge, this paper makes the
first attempt to comprehensively analyze CMSs. Our study
demonstrated that immunohistochemical analyses support
differential diagnosis of those rare tumors. Higher expres-
sion levels of Vim were correlated with the histological
type of the evaluated sarcoma. Ki67 expression was asso-
ciated with tumor grade. Further work is required to vali-
date our results on a larger number of samples.
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